Onkos Surgical enrolled the first patient in its Post-Market Surveillance Study of the ELEOS Limb Salvage System with NanoCept Antibacterial Implant Technology. This first and only orthopedic antibacterial coating technology available on the U.S. market offers a proactive approach against intraoperative bacterial contamination.
Over 100 patients will be enrolled in a multicenter study across the United States.
Since its first use in December 2024, the orthopedic market has shown steadily increasing demand for NanoCept technology. Momentum for new products with NanoCept technology is growing as demonstrated by FDA issuing 510(k) clearance for the ELEOS Proximal Tibia with NanoCept Antibacterial Technology in October 2025. To meet the increasing demand, Onkos opened its NanoCept Innovation Center in Bridgewater, NJ in December 2025 to expand production capacity for this exciting technology.
“The enrollment of the first patient in this study marks another major milestone in the NanoCept journey, and reinforces our firm commitment to individuals with complex orthopaedic conditions,” said Patrick Treacy, Onkos Surgical CEO and Co-founder. “We look forward to executing this study, as part of our agreement with FDA in conjunction with our original De Novo authorization, and continuing to bring this novel technology to surgeons and patients in need. We are very excited about the potential to help patients with this transformational technology, the likes of which we have not seen in 30 years.”
Onkos Surgical enrolled the first patient in its Post-Market Surveillance Study of the ELEOS Limb Salvage System with NanoCept Antibacterial Implant Technology. This first and only orthopedic antibacterial coating technology available on the U.S. market offers a proactive approach against intraoperative bacterial contamination.
Over 100...
Onkos Surgical enrolled the first patient in its Post-Market Surveillance Study of the ELEOS Limb Salvage System with NanoCept Antibacterial Implant Technology. This first and only orthopedic antibacterial coating technology available on the U.S. market offers a proactive approach against intraoperative bacterial contamination.
Over 100 patients will be enrolled in a multicenter study across the United States.
Since its first use in December 2024, the orthopedic market has shown steadily increasing demand for NanoCept technology. Momentum for new products with NanoCept technology is growing as demonstrated by FDA issuing 510(k) clearance for the ELEOS Proximal Tibia with NanoCept Antibacterial Technology in October 2025. To meet the increasing demand, Onkos opened its NanoCept Innovation Center in Bridgewater, NJ in December 2025 to expand production capacity for this exciting technology.
“The enrollment of the first patient in this study marks another major milestone in the NanoCept journey, and reinforces our firm commitment to individuals with complex orthopaedic conditions,” said Patrick Treacy, Onkos Surgical CEO and Co-founder. “We look forward to executing this study, as part of our agreement with FDA in conjunction with our original De Novo authorization, and continuing to bring this novel technology to surgeons and patients in need. We are very excited about the potential to help patients with this transformational technology, the likes of which we have not seen in 30 years.”
Copy to clipboard 
